All In Biotech

NDA 020191 · Novartis

Alomide

Lodoxamide Tromethamine · Ophthalmic

NovelOrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Jun 26, 2003 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Sep 23, 1993

Approved uses

1

Original approval plus efficacy supplements

Registered trials

0

0 Phase 3, 0 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 23, 1993 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • ALOMIDE · LODOXAMIDE TROMETHAMINE EQ 0.1% BASE · SOLUTION/DROPS, OPHTHALMIC · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Lodoxamide Tromethamine" as an intervention, any sponsor and status, largest first.

All 0 trials

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Alomide (Lodoxamide Tromethamine)

2024 spending

$92K

Beneficiaries

182

374 claims

Per beneficiary

$505

$19.97 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$64,109
2024$91,853

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 14 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.